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Although the worldwide incidence of HIV infection is high, the retrovirus displays a surpris-
ingly low infectivity in vitro. As a potential explanation for this discrepancy, Münch et al. 
(2007) now identify and characterize a factor found in human semen that under certain 
conditions can enhance HIV infectivity by more than 100,000-fold.Over the past 25 years, HIV has 
emerged as a pressing threat to 
human health. HIV has already cost 
25 million human lives, and an esti-
mated 2 million people continue to 
die every year as a result of AIDS 
(UNAIDS, 2007). Although the HIV 
pandemic continues to expand, the 
retrovirus itself is a surprisingly weak 
pathogen in terms of its overall infec-
tivity: in vitro, only one in every 1,000 
to 100,000 viral particles is infectious 
(Dimitrov et al., 1993; Rusert et al., 
2004). What explains the discrep-
ancy between the low infectivity of 
HIV virions in vitro and the high inci-
dence of new infections worldwide? 
The answer may lie in part with host 
factors that potentiate the person-to-
person spread of HIV. In this issue, 
Münch et al. (2007) provide support 
for this notion by detecting a human 
factor in semen that under certain 
circumstances can enhance HIV 
infectivity by more than five orders of 
magnitude.
The most common mode of HIV 
transmission is sexual contact 
between a male donor and a female 
recipient, with semen serving as the 
infectious fluid. An attractive hypoth-
esis is that semen contains one or 
more factors that protect HIV virions 
or enhance their transmission. This 
hypothesis is strengthened by the 
observation that replication-compe-
tent HIV can be detected in semen 
even when antiretroviral drugs are 
present at 10-fold higher concentra-
tions in seminal fluid than in blood 1044 Cell 131, December 14, 2007 ©2007(Pomerantz, 2003). Indeed, a num-
ber of components of seminal fluid, 
whose physiological purpose is to 
protect spermatozoa during their 
journey to a female’s egg, can also 
protect HIV virions. For example, 
basic amines such as spermine, sper-
midine, putrescine, and cadaverine 
commonly protect both spermato-
zoa and HIV virions from the threat of 
acid inactivation in the vaginal tract. 
In addition to amines, seminal fluid 
contains a variety of nutrients and 
enzymes produced by the prostate, 
seminal vesicles, and bulbourethal 
glands. Proteomic analysis of semi-
nal fluid has identified more than 900 
proteins (Fung et al., 2004; Pilch and 
Mann, 2006; Starita-Geribaldi et al., 
2001). One or more of these proteins 
might also influence the efficiency of 
HIV transmission.
In their new findings, Münch et al. 
not only demonstrate that semen 
does enhance HIV infectivity, but 
they further identify and characterize 
a specific peptide that contributes to 
this activity. From a complex pep-
tide/protein library prepared from 
pooled human semen, they identified 
a fraction that consistently enhanced 
HIV infectivity. Sequencing and mass 
spectroscopic analysis of this fraction 
revealed the enhancing factors to be 
peptide fragments generated from 
an internal region of prostatic acid 
phosphatase (PAP), a protein pro-
duced by the prostate and secreted 
into semen in milligram quantities. 
The major peptide in the enhanc- Elsevier Inc.ing fraction, residues 248–286 from 
PAP, is present at a concentration 
of ~35 µg/ml in pooled semen sam-
ples. At concentrations ≥0.8 µg/ml, 
chemically synthesized PAP248-286 
broadly enhances infection by R5-, 
X4-, and dual-tropic HIV-1 strains as 
well as more divergent group M and 
O strains. Furthermore, the peptide 
enhances both direct and trans-in-
fection of multiple cell lines and pri-
mary cells isolated from human ton-
sillar tissue and peripheral blood.
Remarkably, when the effects of 
the peptide are assessed under con-
ditions of limiting viral inoculum, the 
enhancement of viral infectivity can 
exceed five orders of magnitude. 
By calculating the number of viri-
ons in their virus stocks, Münch et 
al. conclude that only one to three 
virions are sufficient for produc-
tive HIV infection in the presence of 
physiological concentrations of the 
semen-derived peptide. Conversely, 
in the absence of the peptide, 1,000–
100,000 HIV particles are typically 
necessary to observe productive 
infection (Münch et al., 2007). These 
findings raise the possibility that 
the low ratio of infectious to nonin-
fectious virions found in most viral 
samples could relate more to the 
ineffective delivery of virions to tar-
get cells (Thomas et al., 2007) rather 
than the presence of large numbers 
of defective particles. Of course, it 
is possible that both mechanisms 
are in play. Studies of this peptide 
in the presence of limiting amounts 
of virus may in fact recapitulate 
the situation encountered during 
heterosexual transmission where 
the virus appears to struggle to 
establish an effective “beach-
head” of infection.
Intriguingly, the story contains 
a further twist that was discov-
ered serendipitously. With the 
sequence of the peptide in hand, 
Münch and colleagues chemi-
cally synthesized PAP248-286 
and tested it for enhancing activ-
ity. Surprisingly, the freshly syn-
thesized peptide was completely 
inactive. However, when the 
peptide was retested after either 
short-term storage or agitation, 
activity was readily detected. 
The investigators noted that 
development of enhancing activ-
ity correlated with the appear-
ance of turbidity in the peptide 
solution. They centrifuged the 
turbid solution and discov-
ered that the enhancing activity 
resided entirely within the pel-
leted fraction. Further analysis 
employing a variety of biophysi-
cal techniques revealed that the 
turbid PAP248-286 solution was 
laden with amyloid fibrils. These 
fibrils appeared to bind to viri-
ons and were captured by cel-
lular protrusions, leading to a 
marked increase in the attach-
ment of the virions to target cells. 
The authors named these fibrils 
semen-derived enhancer of viral 
infection, or SEVI.
Is there a precedent for amy-
loid fibril-mediated enhancement 
of HIV infection? Indeed, stud-
ies have shown that β-amyloid 
fibrils can also enhance HIV infection 
in a coreceptor-dependent manner, 
albeit with lower efficiency (Wojtow-
icz et al., 2002). Therefore, in addi-
tion to its widely recognized role in 
neurodegenerative diseases, the 
amyloid fold may also play a key role 
in HIV transmission.
These latest advances establish 
a model whereby PAP248-286, after 
proteolytic cleavage from its poly-
peptide precursor, aggregates to 
form SEVI amyloid fibrils (Figure 1). 
These fibrils bind directly to the HIV 
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inigure 1. Enhancement of HIV Infection by SEVI
rostatic acid phosphatase (PAP), an abundant pro-
in in semen, is cleaved into the PAP248-286 peptide, 
hich then aggregates to form amyloid fibrils termed 
emen-derived enhancer of viral infection (SEVI) 
ünch et al., 2007). The fibrils capture HIV virions and 
irect them to target cells to which they fuse. Under 
onditions of a limiting viral inoculum, SEVI enhances 
fectivity of HIV virions by more than 100,000-foldvirions and enhance their infectivity 
by efficiently delivering them to tar-
get cells to which they fuse. During 
male-to-female transmission, the 
major targets of SEVI-coated viri-
ons are presumably HIV-permissive 
cells in the genital mucosa. However, 
whether SEVI indeed enhances HIV 
infection of primary cells isolated 
from the vagina, cervix, and endo-
metrium remains to be determined.
As with most significant advances, 
this paper raises a whole series of 
new questions. First, how do SEVI Cell 131, Decemfibrils enhance HIV infectivity? 
Although improved virion attach-
ment appears to be involved, 
what properties of SEVI lead to 
this change? As noted, not all 
amyloid fibrils equally enhance 
HIV infection (Münch et al., 2007), 
suggesting that the primary 
sequence of the peptide may 
be important. Second, how and 
where is fully active SEVI formed? 
In particular, the protease that 
releases PAP248-286 from its 
polypeptide precursor remains 
unknown, and the conditions that 
favor the seeding and amplifica-
tion of SEVI fibrils are similarly 
undefined. It is unclear whether 
these fibrils exist in a completely 
formed state in semen or alterna-
tively whether the mixing of the 
basic semen and acidic vaginal 
fluids accelerates fibril forma-
tion. And finally, do SEVI fibrils 
have a function in normal human 
reproduction, or are they simply 
an accident of protein misfolding 
that unfortunately facilitates HIV 
infection?
Of note, the overall frequency 
of heterosexual HIV transmis-
sion per sexual act is only about 
0.0001 to 0.001, although this 
frequency increases when viral 
loads are especially high in the 
male donor or genital ulcers are 
present in the female recipient 
(Gray et al., 2001). If SEVI truly 
increases the real world hetero-
sexual spread of HIV by sev-
eral orders of magnitude, then 
negating the activity of this fac-
tor could conceivably diminish 
these frequencies to levels that 
might virtually eliminate semen-
driven HIV transmission. Such a 
host-directed strategy for impairing 
HIV transmission is unlikely to select 
for the rapid emergence of drug-
resistant viral strains so charac-
teristic of virus-directed therapies. 
However, to design ways to inhibit 
the activity of SEVI, we first need to 
better understand its mechanisms 
of generation and action. The future 
promises a series of rapid and 
important advances as the SEVI 
story unfolds further.ber 14, 2007 ©2007 Elsevier Inc. 1045
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